Molecular Formula | C18H25N5S2 |
Molar Mass | 375.55 |
Density | 1.36±0.1 g/cm3(Predicted) |
Boling Point | 527.9±60.0 °C(Predicted) |
pKa | 9.59±0.40(Predicted) |
Storage Condition | -20℃ |
In vitro study | In HEK293 cells, MI-3 approached the protein target and effectively inhibited the interaction by menin-MLL-AF9. MI-3 the MLL fusion protein-mediated leukemic transformation is effectively blocked by down-regulating the expression of a target gene required for the oncogenic activity of the MLL fusion protein. In human MLL leukemia cell lines carrying different MLL translocations, MI-3 effectively blocked cell differentiation and induced apoptosis. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.663 ml | 13.314 ml | 26.628 ml |
5 mM | 0.533 ml | 2.663 ml | 5.326 ml |
10 mM | 0.266 ml | 1.331 ml | 2.663 ml |
5 mM | 0.053 ml | 0.266 ml | 0.533 ml |
use | MI-3 (Menin-MLL inhibitor) can inhibit the carcinogenic activity of MLL fusion protein in leukemia. |
biological activity | MI-3 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 648 nM. |
In vitro study | In HEK293 cells, MI-3 approach protein targets and effectively inhibit menin-MLL-AF9 interactions. MI-3 can effectively block the transformation of leukemia mediated by MLL fusion protein by down-regulating the expression of target genes required for oncogenic activity of MLL fusion protein. In human MLL leukemia cell lines carrying different MLL translocation, MI-3 effectively block cell differentiation and induce cell apoptosis. |
target | IC50: 648 nM (menin-MLL); Kd: 201 nM (menin-MLL) |